Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Alliance Bernstein CGM Disruptors Conference 2021
21 slides from Nemaura Medical's conference presentation, Nov 18, 2021
Slide 1: Alliance Bernstein CGM Disruptors Conference
Alliance Bernstein CGM Disruptors Conference 19 th November 2021 Dr Faz Chowdhury, CEO Nasdaq : NMRD
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms such
Slide 3: The Problem
The Problem… There are over 463 million people living with diabetes worldwide, and over $ 760 Billion was spent in the US alone in 2019 for diabetes related healthcare expenditure 1 . The total addressable market exceeds $ 150 Billion 2 , 3 , 4 . Obesity and Diabetes are two of the major drivers of
Slide 4: Why CGM? BGM Misses the full picture!
Why CGM? BGM Misses the full picture!
Slide 5: Nemaura's Vision
Nemaura’s Vision Lead in the Prevention, Management, & Reversal of Type 2 Diabetes using a low cost, flexible, user - friendly device and digital ecosystem.
Slide 6: Our Approach
Our Approach 1. Skin mounted (disposable) sensor & (non - disposable) transmitter. Glucose extracted to the surface of the skin 1. S ensors use well established glucose Oxidase enzyme to convert glucose to an electric current signal 1. Low energy Bluetooth sends this to the phone app every 5 minutes
Slide 7: sugarBEAT Regulatory Status
sugarBEAT ® Regulatory Status CE Approved Class 2b Medical Device in Europe FDA PMA submitted and in review
Slide 8: sugarBEAT Sales status UK
sugarBEAT ® Sales status UK UK: 200,000 Sensors ordered by licensee following soft launch success Purchase order forecast for (approximately) a further 100,000 per month for the next 2 years, totaling over 2 million sensors. Licensee selling these based on a diabetes management subscription service.
Slide 9: sugarBEAT Outside-UK
sugarBEAT ® Outside - UK Planning direct to consumer launch of sugarBEAT outside of UK where CE approval is accepted, such as Europe and Middle East.
Slide 10: Product Positioning
Product Positioning sugarBEAT® CGM – Direct sales to consumers that wish to purchase sensors to measure glucose profiles on days they choose. www.sugarBEAT.com BEAT®diabetes Program: A diabetes management program based on subscription. Currently in Pilot and plan is to sell in to Corporates and Insu
Slide 11: sugarBEAT How it works
sugarBEAT” rning, : ; 9 ecamanename How it works J You in your target ronge © clucore lve ) Time I E 09:03 @ id ee See changes as they happen Helps you understand your unique glucose trend line and lifestyle choices taken.
Slide 12: sugarBEAT Testimonials
sugarBEAT ® Testimonials My Sugar Watch offered me a needle - free blood glucose monitoring solution that’s non - invasive and easy to use. I didn’t even realize I had the My Sugar watch device on my arm as it is so lightweight. It gives me the assurance that my blood sugar reading is accurate, and
Slide 13: Type 2 Diabetes prevention and management program launched in the U.S.
Type 2 Diabetes prevention and management program launched in the U.S.
Slide 14: BEATdiabetes – Components
BEAT ® diabetes – 3 Components 1. Weight loss program originally developed at the Joslin Diabetes Centre – over 12 years of clinical evidence (based on an in - clinic program, subsequently replicated using a virtual program). Sustained long term weight loss achieved without loss of muscle mass 1. pr
Slide 15: Miboko 'Mind Body Connect'
Miboko ‘MIND BODY CONNECT’ A metabolic health program comprising an app and integrated glucose sensor
Slide 16: MiBoKo: A Mass-Market Consumer Product
MiBoKo : A Mass - Market Consumer Product Download the app & On - board Sensor measures metabolic health score Receive report and weekly targets Applicable to over 80 million people in the U.S. with prediabetes as well as general health - conscious individuals, and obesity market.
Slide 17: Future Product Opportunities: Lactate and Body Temperature Monitoring
CONTINUOUS LACTATE MONITORING Assists in threshold maximization in performance athletes Early identification of tissue hypoperfusion or shock for aggressive early resuscitation of critically ill patients to improve the their chances of survival BODY TEMPERATURE MONITORING Gives a more accurate and l
Slide 18: Future Product Opportunities: Alcohol and Drug Monitoring
ALCOHOL MONITORING Support personal health goals and provide warnings prior to driving. Provide physicians with individual’s drinking habits . Prevention of progression - to - alcohol - related disease DRUG MONITORING Monitoring the impact of drugs and personalized treatment plan for patients. Globa
Slide 19: The Team
The Team We are building a world class team So far includes senior level appointments, with experience from companies including: Dexcom, Lifescan , Roche, Abbvie , & Eli Lilly
Slide 20: Summary
Summary 1. CE Class 2b Medical Device Approval – and subsequent user testimonials and order for 200,000 sensors (from UK Licensee) is validation of the technology 1. FDA PMA review is in progress 1. No other product offers daily sensing in this way (that we are aware of) giving us a a first mover ad
Slide 21: References
References 1. https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures. htm! 3. https://www.prnewswire.com/news-releases/global-digital-diabetes-market- outlook-to-2026-a-16-billion-industry-opportunity-300980794.htm! 4, https://www.absolutemarketsinsights.com/reports/Global-Noninsulin- ‘The
Nemaura Medical — Alliance Bernstein CGM Disruptors Conference 2021 on 6ix